MEDIOCON INC – Laropiprant is a synthetic small-molecule prostaglandin D₂ (PGD₂) receptor DP1 antagonist. It has been investigated for its ability to inhibit PGD₂-mediated vasodilation and was developed particularly in combination with niacin to reduce niacin-associated cutaneous flushing. Laropiprant is also known by the development code MK-0524.
Laropiprant is an indolyl carboxylic acid derivative and a selective antagonist of the prostaglandin D₂ receptor DP1. By competing with prostaglandin D₂ at the DP1 receptor, Laropiprant can inhibit PGD₂-induced vasodilation and increased skin blood flow.
The compound was investigated as an adjunct to extended-release niacin formulations, where inhibition of the DP1 receptor was intended to reduce niacin-induced flushing.
Product Name: Laropiprant
CAS Number: 571170-77-9
Molecular Formula: C₂₁H₁₉ClFNO₄S
Molecular Weight: Approximately 435.9 g/mol
Chemical Class: Indolyl carboxylic acid / DP1 receptor antagonist
Synonyms: MK-0524, MK 0524, Laropiprantum
PubChem CID: 9867642
ChEBI ID: CHEBI:135942
DrugBank ID: DB11629
Laropiprant selectively antagonizes the prostaglandin D₂ DP1 receptor, a G-protein-coupled receptor. PGD₂ is involved in vasodilation and increased cutaneous blood flow. By blocking DP1 receptor signaling, Laropiprant inhibits PGD₂-induced vasodilation and was investigated for reduction of niacin-associated facial and cutaneous flushing.
MEDIOCON INC focuses on supplying pharmaceutical and specialty chemical ingredients with emphasis on quality, consistency, technical documentation and reliable supply.
Laropiprant quality evaluation may include identity, assay, chromatographic purity, related substances, residual solvents, water content, residue on ignition and other parameters according to the applicable product specification.
The exact analytical acceptance criteria should be confirmed against the current approved specification and batch-specific Certificate of Analysis.
Laropiprant has been investigated primarily as a DP1 receptor antagonist and as an agent for reducing niacin-induced flushing. It was incorporated into the development of combination products containing extended-release niacin.
The European Medicines Agency records Laropiprant as an ingredient in the withdrawn product Pelzont. Therefore, it should not be presented as a currently approved therapeutic product without confirming the regulatory status applicable to the intended market.
Laropiprant is a defined synthetic small molecule with molecular formula C₂₁H₁₉ClFNO₄S and molecular weight approximately 435.9 g/mol. The primary compound is identified by CAS 571170-77-9.
PubChem also lists a deprecated CAS number of 895565-43-2; the current primary CAS should be represented as 571170-77-9.
Product availability, packaging configuration, Certificate of Analysis (COA), Safety Data Sheet (SDS/MSDS), technical specifications and other documentation should be confirmed with MEDIOCON INC according to the intended application and customer requirements.
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Laropiprant API Manufacturer and Supplier in India (CAS 571170-77-9) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Laropiprant API Manufacturer and Supplier in India is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing before release with a Certificate of Analysis.
Export Markets
Quality & Compliance